Drugs / mesoangioblasts
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05063721 | Mar 2020 → Sep 2022 | pure mitochondrial myopathy | Maastricht University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05962333 | Aug 2023 → Aug 2024 | pure mitochondrial myopathy | Maastricht University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesoangioblasts | “three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval” NCT05962333 ↗ |
| Known as | MABs | “Myogenic stem cells called mesoangioblasts (MABs), are currently the only myogenic precursors” NCT05063721 ↗ |
| Modality | Cell therapy | “Myogenic stem cell-based therapies complementing defective muscle cells and fibres” NCT05063721 ↗ |
| Route | Other | “intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)” NCT05063721 ↗ |